IL191795A - Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system - Google Patents

Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system

Info

Publication number
IL191795A
IL191795A IL191795A IL19179508A IL191795A IL 191795 A IL191795 A IL 191795A IL 191795 A IL191795 A IL 191795A IL 19179508 A IL19179508 A IL 19179508A IL 191795 A IL191795 A IL 191795A
Authority
IL
Israel
Prior art keywords
treatment
bacillus
prophylaxis
immuno
medicaments
Prior art date
Application number
IL191795A
Other languages
English (en)
Hebrew (he)
Other versions
IL191795A0 (en
Original Assignee
Kemin Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Ind Inc filed Critical Kemin Ind Inc
Publication of IL191795A0 publication Critical patent/IL191795A0/en
Publication of IL191795A publication Critical patent/IL191795A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL191795A 2005-11-29 2008-05-28 Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system IL191795A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Publications (2)

Publication Number Publication Date
IL191795A0 IL191795A0 (en) 2009-02-11
IL191795A true IL191795A (en) 2013-07-31

Family

ID=38092773

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191795A IL191795A (en) 2005-11-29 2008-05-28 Use of Bacillus 6pb for the preparation of drugs for the prevention or treatment of gastrointestinal and related disorders @ the @ immune system

Country Status (13)

Country Link
US (1) US20080057047A1 (enExample)
EP (1) EP1956914B1 (enExample)
JP (2) JP5280854B2 (enExample)
KR (1) KR101470352B1 (enExample)
CN (1) CN101448398B (enExample)
AU (1) AU2006320613B2 (enExample)
BR (1) BRPI0619364A2 (enExample)
CA (1) CA2631289C (enExample)
IL (1) IL191795A (enExample)
NZ (1) NZ569244A (enExample)
RU (1) RU2412241C2 (enExample)
WO (1) WO2007064741A2 (enExample)
ZA (1) ZA200804646B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BRPI0918033A8 (pt) * 2008-09-17 2017-10-03 Agraquest Inc Metodo para melhorar a saude de um animal nao inseto e nao humano, e, composicao para melhorar a condicao fisica de um animal nao inseto e nao humano
WO2010034776A1 (en) * 2008-09-24 2010-04-01 Universiteit Gent Incorporation of thermo-resistant and/or pressure-resistant organisms in materials
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
WO2011116155A1 (en) 2010-03-17 2011-09-22 Agraquest, Inc. Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
BR112013001107B1 (pt) 2010-07-16 2022-01-25 The Board Of Trustees Of The University Of Arkansas Métodos e composições incluindo bactéria formadora de esporos para aumento da saúde dos animais
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
EP2661500A2 (en) * 2010-12-29 2013-11-13 Cangene Corporation Clostridium difficile antigens
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) * 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
CA2956179C (en) * 2014-07-25 2023-12-12 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
WO2016054222A1 (en) 2014-09-30 2016-04-07 Auburn University Use of pectin or pectin-related saccharides to enhance efficacy of plant growth-promoting rhizobacteria (pgpr) strains for promoting growth and health in plants and animals
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
ES2759300T3 (es) 2015-01-23 2020-05-08 Novozymes As Subespecies de Bacillus subtilis
CN107567493B (zh) * 2015-01-23 2021-11-16 诺维信公司 改进生产动物的健康和性能的芽孢杆菌属菌株
BR112017015623B1 (pt) 2015-01-23 2022-05-31 Novozymes A/S Ração animal ou aditivo de ração animal ou pré-mistura de ração, método para melhora de um ou mais parâmetros de desempenho de um animal e para alimentação de um animal, e, uso de uma cepa de bacillus
CA2987013C (en) * 2015-05-30 2022-05-31 Japan Eco-Science Co., Ltd. Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine
WO2017062175A1 (en) * 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
TWI636739B (zh) * 2015-10-26 2018-10-01 南韓商Ｃｊ第一製糖股份有限公司 解澱粉芽孢桿菌、穀物醱酵物、其製備方法及其用途、食品組成物、血栓分解用組成物、消化改善用組成物、腸炎、腸膜弱化或腸損傷的預防、改善或治療用組成物及抗氧化用組成物
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
MX2020000182A (es) 2017-06-30 2020-07-22 Evonik Operations Gmbh Cepa bacillus subtilis con actividad probiotica.
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
CA3102263A1 (en) * 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile
EP3969023A1 (en) * 2019-05-14 2022-03-23 Ormendes SA <smallcaps/>? ? ?bacillus amyloliquefaciens? ? ? ? ?use ofand/or <ns1:i>bacillus subtilis</ns1:i>?for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related method
US12377122B2 (en) 2019-06-21 2025-08-05 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) * 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
US20210283199A1 (en) * 2020-03-13 2021-09-16 Kemin Industries, Inc. Method for controlling clostridium infection in animals
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
MX2023006676A (es) 2020-12-09 2023-07-04 Purina Animal Nutrition Llc Composiciones alimenticias y metodos para inhibir dermatitis ulcerosa focal.
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
KR102546973B1 (ko) * 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
DE29724815U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
KR100535912B1 (ko) * 2003-12-17 2005-12-09 주식회사 케이티앤지 신규한 미생물 바실러스 아밀로리쿼페이션스 케이티지비0202 및 이를 이용한 식물병원균의 방제방법
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Also Published As

Publication number Publication date
RU2412241C2 (ru) 2011-02-20
KR101470352B1 (ko) 2014-12-09
WO2007064741A3 (en) 2008-05-08
AU2006320613A1 (en) 2007-06-07
AU2006320613B2 (en) 2012-08-16
JP5280854B2 (ja) 2013-09-04
NZ569244A (en) 2012-07-27
CA2631289A1 (en) 2007-06-07
EP1956914A2 (en) 2008-08-20
IL191795A0 (en) 2009-02-11
ZA200804646B (en) 2011-11-30
US20080057047A1 (en) 2008-03-06
CN101448398B (zh) 2013-05-08
CA2631289C (en) 2015-01-06
EP1956914B1 (en) 2014-01-08
JP2009519238A (ja) 2009-05-14
WO2007064741A2 (en) 2007-06-07
KR20080073771A (ko) 2008-08-11
JP2013173750A (ja) 2013-09-05
EP1956914A4 (en) 2011-12-21
RU2008121602A (ru) 2009-12-10
WO2007064741A8 (en) 2008-01-31
BRPI0619364A2 (pt) 2011-09-27
CN101448398A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
WO2007064741A8 (en) The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
Lebeer et al. Identification of probiotic effector molecules: present state and future perspectives
JP2009519238A5 (enExample)
GB2460781A (en) Probiotic bifidobacterium strains
MY146590A (en) Probiotic bifidobacterium strains
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
Bolla et al. Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection
NZ603065A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
UA100551C2 (en) Synbiotic mixture
WO2008077614A3 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
AU2006253006A8 (en) Feline probiotic Lactobacilli
NZ593708A (en) Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
SE0402406D0 (sv) Probiotic lactobacillus strains for improved vaginal health
MX2009012255A (es) Probioticos en ambiente pre y/o postquirurgico.
WO2007136719A3 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
PH12013501408A1 (en) A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
MX339951B (es) Bacillus subtilis aislado de maiz.
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
RU2014107771A (ru) ШТАММЫ МОЛОЧНО-КИСЛЫХ БАКТЕРИЙ И/ИЛИ БИФИДОБАКТЕРИЙ, ИНГИБИРУЮЩИЕ/УМЕНЬШАЮЩИЕ РОСТ РАЗЛИЧНЫХ БИОТИПОВ E.coli И РАЗЛИЧНЫХ БИОТИПОВ КЛОСТРИДИЙ
JP2013147469A5 (enExample)
DK1624762T3 (da) Probiotisk præparat med mindst to mælkesyrebakteriestammer som er i stand til kolonisere mavetarmkanalen, i kombination med at de besidder overlevelsesegenskab, tarmbindende egenskab, en infektionsbeskyttelsesegenskab og en fiberfermenterende egenskab
WO2005112976A3 (en) Probiotic compounds from lactobacillus gg and uses therefor
Mahdhi et al. Survival and retention of the probiotic properties of Bacillus sp. strains under marine stress starvation conditions and their potential use as a probiotic in Artemia culture
Nuñez et al. Caracterización genética de bacterias endofíticas de arroz (Oryza sativa L.) con actividad antimicrobiana contra Burkholderia glumae
Jiang et al. Protective effects of Bacillus amyloliquefaciens 40 against Clostridium perfringens infection in mice

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees